Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1/PD-L1 for prostate cancer: from clinical trials to practice.

Expert review of clinical pharmacology - 1 Apr 2026

Holmes Aaron, Okobi Tobechukwu, Arham Abdul Baseet, Vaishampayan Neil, Subramanya Deepthi, Tagawa Scott T

Abstract excerpt

INTRODUCTION: A growing number of malignancies have shown favorable responses to immune checkpoint inhibitors (ICI), most commonly anti-PD-(L)1 antibodies. However, prostate cancer has been associated with mostly unfavorable responses to ICI. This review discusses various trials related to PD-(L)1 inhibitors in prostate cancer. AREAS COVERED: We wrote a review article based upon content and practice expertise...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Mutation

Share to Programmed Cell Death 1 Receptor

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 41914824
DOI: 10.1080/17512433.2026.2649610

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1/PD-L1 for prostate cancer: from clinical trials to practice.PMID 41914824Read ↗

Treatment strategies for DNA repair-deficient prostate cancer.Semantic proximity Read ↗

Clinical Implications of Mismatch Repair Deficiency in Prostate CancerSemantic proximity Read ↗

Emerging Biomarker-Guided Therapies in Prostate CancerSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.Semantic proximity Read ↗

An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKTSemantic proximity Read ↗

Immunotherapy for Prostate Cancer: Treatments for the "Lethal" Phenotype.Semantic proximity Read ↗

PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?Semantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.Semantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.